Carbinol compound having a heterocyclic linking group

The present invention provides novel LXRβ agonist as atherosclerosis and other preventive and / or therapeutic agent. LXRβ agonists of the invention are methanol compound of the following formula (I) as shown, or a salt or solvate thereof, [Chemical Formula 1] [wherein, V, W each independently represents N or C-R7 , X, Y each independently represents CH2, C = O, SO2, etc., Z represents CH or N, R1, R2, R7 each independently represent a hydrogen atom, a halogen atom, C1-8 alkyl group, R3 is C1-8 alkyl group, R4 represents an optionally substituted C6-10 aryl group or a 5-11 membered heterocyclic group may have a substituent, R5, R6 represents a hydrogen atom, L represents an optionally substituted C1-8 alkoxy oxo group chain group, n represents any integer of 0 to 2].